Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has received an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $8.00.

A number of equities analysts have commented on HCAT shares. KeyCorp cut their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Piper Sandler cut their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Stifel Nicolaus increased their price target on Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a report on Thursday, May 8th. Citigroup lowered their price objective on Health Catalyst from $7.00 to $6.50 and set a “buy” rating for the company in a research note on Friday, April 25th. Finally, Evercore ISI lowered Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday, April 9th.

Insider Activity

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company’s stock, valued at $729,988.35. The trade was a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Daniel Lesueur sold 16,902 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares in the company, valued at approximately $977,450. The trade was a 7.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,147 shares of company stock worth $182,284. 2.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently bought and sold shares of HCAT. Quantbot Technologies LP acquired a new stake in shares of Health Catalyst during the 4th quarter worth approximately $29,000. Group One Trading LLC grew its stake in Health Catalyst by 107.6% during the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after buying an additional 2,260 shares during the last quarter. Focus Partners Wealth acquired a new stake in Health Catalyst in the first quarter worth $46,000. XTX Topco Ltd acquired a new stake in Health Catalyst in the first quarter worth $54,000. Finally, Aquatic Capital Management LLC bought a new stake in Health Catalyst in the fourth quarter valued at $63,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Trading Down 0.3%

NASDAQ HCAT opened at $3.65 on Monday. The stock has a market cap of $254.04 million, a P/E ratio of -2.70 and a beta of 1.56. The company’s fifty day simple moving average is $4.07 and its 200-day simple moving average is $5.67. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 52 week low of $3.54 and a 52 week high of $9.24.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.